Wolfe Research analyst Rudy Li initiated coverage of Acadia Pharmaceuticals (ACAD) with an Outperform rating and $33 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe believes Acadia’s base business of Nuplazid and Daybue just the current share price.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals upgraded to Outperform from Neutral at Mizuho
- ACAD Upcoming Earnings Report: What to Expect?
- ACADIA’s ACP-211 Trial Targets Difficult-to-Treat Depression: What Investors Should Watch
- Acadia Pharmaceuticals price target raised to $23 from $21 at Oppenheimer
- ACADIA Pharmaceuticals: U.S. Commercial Execution and Pipeline Optionality Drive Undervalued Buy Thesis Despite EU Trofinetide Delay